Androgen ablation is palliative and does not cure advanced prostate cancer. The hormone-sensitive cells die and the hormone-resistant cells overgrow, resulting in disease progression. The drug of choice for secondary treatment is estramustine (Estracyt). The success of the therapy is followed by changes of the prostate-specific antigen level and Karnofsky scale. In the present study, the result...

Prostate cancer is a prevalent problem in male healthcare. The previous decades have witnessed some significant improvements the knowledge of aetiology and pathology, as well practice screening, treatment, follow-up disease. A downstaging at time diagnosis increase survival were vivid with advancements, albeit screening disease using regular prostate specific antigen measurements was previously...

OBJECTIVES To explore the attitudes of men with confirmed or suspected prostate cancer to testing for prostate specific antigen. DESIGN Qualitative interview study with a purposive sample. SETTING Great Britain. PARTICIPANTS 52 men with suspected or confirmed prostate cancer, recruited through general practitioners, urologists, patient support groups, and charities. RESULTS Almost all m...

BACKGROUND Prostate-specific antigen (PSA) assays have historically produced different results. Our aim was to investigate the comparability of assay results of selected commercially available assay methods designed to measure total, free, or complexed PSA (tPSA, fPSA, and cPSA). METHODS We measured tPSA, fPSA, and cPSA in 70 samples and in the WHO PSA 96/670 reference preparation with 6 assa...

The aim of this study is to evaluate the ability of the random forest algorithm that combines data on transrectal ultrasound findings, age, and serum levels of prostate-specific antigen to predict prostate carcinoma. Clinico-demographic data were analyzed for 941 patients with prostate diseases treated at our hospital, including age, serum prostate-specific antigen levels, transrectal ultrasoun...

objective(s): the aim of this study was to analyze detection rates and effectiveness of 18f-fluorodeoxyglucose positron emission tomography (fdg-pet) cancer screening program for prostate cancer in japan, which is defined as a cancer-screening program for subjects without known cancer. it contains fdg-pet aimed at detection of cancer at an early stage with or without additional screening tests ...

5 Background: It is largely unknown whether prostate-specific antigen at first date of testing predicts long-term risk of prostate cancer incidence and mortality in the general population. We tested the hypothesis that baseline prostate-specific antigen levels predict long-term risk of prostate cancer incidence and mortality. METHODS Using a prospective study, we examined 4383 20-94 year old ...

Introduction Prostate biopsy is commonly performed using a transrectal ultrasound probe through or transperineal approach. However, this not possible for patients without rectum. Case presentation A 75‐year‐old male was referred to our hospital because of an elevated prostate‐specific antigen and suspicious prostate lesion (PIRADS 5) in the left peripheral zone. The patient had previously under...

OBJECTIVE Abiraterone acetate has been approved in >70 countries for chemotherapy-naïve metastatic castration-resistant prostate cancer patients. Efficacy and safety of abiraterone acetate (1000 mg/once daily) with prednisolone (5 mg/twice daily) in chemotherapy-naïve Japanese patients with metastatic castration-resistant prostate cancer was evaluated. METHODS Men, ≥20 years, with prostate-sp...